Stem Cells Live: An Investor’s Guide to Stem Cells

‘People have no idea how well the industry is doing right now’ These were the words of Conkos Securities’ Navid Malik during his presentation this morning. And he wasn’t alone in singing the praises of the industry and it’s financial performance over the last few years. Both Greg Bonfiglio, MD Proteus Venutre Partners, and Dr Michael West, CEO BioTime, also …

Pharma M&A AstraZeenec and Pfizer Chess Game

Pharma M&A Chess: Who moves next – AstraZeneca or Pfizer?

Pfizer’s intentions on AstraZeneca involve the playing of a high stakes strategic chess game, with each side plotting carefully their next move. Pfizer has until May 26th to make a firm bid on AstraZeneca or walk away and with the episode in the public eye, it will be interesting to see what moves each company makes in the next few …

big pharma firepower in global pharma m&a

Big pharma’s position in global pharma M&A – exploring EY’s ‘Firepower’ report

Last year saw pharmaceutical mergers and acquisitions increase by $45 billion (click here to read a recent Total Biopharma post about it). However, the activities of big pharma in these M&As were somewhat marginalised, with the majority of acquisitions completed by speciality pharma and big biotech. As reported in Financier.com, Ernst & Young’s report, ‘Firepower and Growth Gap’, states that …

pharma m&a

Strong pharma M&A activity expected in 2014

After poor performance in 2012, it appears that pharma M&A has rebounded! According to a recent PwC report, the pharma industry saw deal value increase by $45 billion in 2013—a 45.8% increase from 2012. According to PwC’s U.S. Pharmaceutical and Life Sciences Deals Leader, Dimitri Drone, they “expect the momentum of M&A activity in the fourth quarter […] to continue into 2014 …